For people with obesity and heart disease, a weekly semaglutide injection lowers the chance of having a heart attack, stroke, or dying from heart problems by 20%, even if their blood sugar doesn’t change.
Claim Context
Subcutaneous semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) by 20% in adults with obesity or overweight and pre-existing cardiovascular disease, independent of changes in HbA1c.
“SELECT studies showed that SMG (Wegovy®) ... reduces the risk of death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke by 20%, which was independent of baseline HbA1c or HbA1c change during the study.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
The pooled effect of semaglutide 2.4 mg on cardiovascular outcomes across all trials in high-risk populations.
A systematic review and meta-analysis of all cardiovascular outcome trials of semaglutide 2.4 mg in adults with obesity and established CVD, pooling hazard ratios for MACE (cardiovascular death, MI, stroke), including at least 2 trials with >10,000 total participants and 2+ years of follow-up.
Causal effect of semaglutide 2.4 mg on reducing MACE in obese patients with CVD.
A double-blind, placebo-controlled RCT of 10,000 adults with BMI ≥30 kg/m² and established CVD, randomized to semaglutide 2.4 mg weekly or placebo for 3 years, with primary outcome: time to first MACE (cardiovascular death, non-fatal MI, non-fatal stroke).
Real-world incidence of MACE in semaglutide users versus non-users with obesity and CVD.
A prospective cohort study of 15,000 adults with obesity and CVD, comparing MACE rates over 5 years between those prescribed semaglutide 2.4 mg and those on other weight-loss or glucose-lowering agents, adjusting for confounders.
Association between semaglutide use and reduced risk of specific cardiovascular events (e.g., stroke vs. MI).
A matched case-control study of 1000 adults with obesity and CVD who experienced a stroke vs. 2000 matched controls without stroke, assessing prior exposure to semaglutide 2.4 mg and duration of use.
Prevalence of cardiovascular events among current semaglutide users in a population.
A cross-sectional survey of 5000 adults with obesity and CVD, asking current medication use and history of heart attack, stroke, or cardiovascular death to estimate event prevalence by semaglutide use.